The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus...
Ethris has partnered Lonza for the development of room-temperature stable mRNA v...
US policy changes to withdraw from the WHO and cut USAID have had clinical reper...
The European Commission (EC) has granted approval for the extension of indicatio...
Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, an...
Late-stage pipeline products anticipated to reach the uveitis market during the ...
The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single...
This week, the Trump administration followed through on its planned mass layoffs...
Streeting said his June 10-year plan will address drug sale clawbacks, NICE regu...
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug ...
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in ...
If preclinical findings were translated into the clinic, they could shorten the ...
At AD/PD 2025, Roche outlined how digital health technologies (DHTs) provide mor...
UK Government drug sale clawbacks must be eased for pharma innovation to meet it...
Atsena Therapeutics has completed an oversubscribed Series C financing round, ra...
Recent innovations include engineering CAR T-cells to overcome the immunosuppres...
